重庆太极实业(集团)股份有限公司2026年第一季度业绩深度解读

核心看点与投资者需关注事项

• 营收与利润双降，扣非净利润大幅下滑：
• 营业收入为25.28亿元，同比下降10.59%。
• 归属于上市公司股东的净利润6,562万元，同比下降11.97%。
• 扣除非经常性损益后的净利润仅为3,857万元，同比下降52.05%。
• 经营性现金流转负，流出规模大幅增加：
• 经营活动产生的现金流量净额为-4.02亿元，去年同期为-1.65亿元，流出大幅扩大，显示公司面临较大的经营资金压力。
• 毛利下降与费用压力并存：
• 受集采及医保政策影响，抗感染药物部分品种销售收入下降，导致毛利额同比下降。
• 市场推广活动加大，销售费用同比大增39.6%，达到5.64亿元。
• 研发费用同比下降33.1%，为5,110万元，或反映公司研发投入有所收缩。
• 非经常性损益对净利润支撑明显：
• 非经常性损益合计2,705万元，主要包括政府补助、金融资产公允价值变动收益等。
• 如果剔除这部分，主营业务利润下滑更为显著。
• 资产负债结构变化：
• 总资产为148.32亿元，季度环比增长2.92%。
• 流动负债环比增加3.55%，至100.52亿元，短期借款高达48.28亿元，显示短期偿债压力较大。
• 货币资金余额降至7.32亿元，环比下降33.5%。
• 股东结构变化：
• 前十大股东中，国有法人控股地位稳固，太极集团有限公司持股27.89%，其中2,834万股处于质押状态。
• 未见明显股权变动或大股东减持迹象。
• 每股收益及净资产收益率下降：
• 基本每股收益为0.12元，同比下降7.69%。
• 加权平均净资产收益率为1.86%，同比下降0.25个百分点。

投资者须重点关注的敏感事项

• 主营业务盈利能力大幅下滑，扣非净利润腰斩，短期内若政策及市场环境未改善，业绩压力或持续。
• 经营现金流出持续扩大，若不能有效改善，公司流动性风险值得警惕。
• 短期借款规模庞大，需关注偿债风险及未来再融资能力。
• 销售费用激增与研发费用下降的趋势，或对公司长期竞争力造成负面影响。
• 非经常性损益对利润的依赖增加，主营业务可持续性存疑。

详细财务数据摘要

• 营业收入：2,528,417,511.83元
• 归母净利润：65,620,375.41元
• 扣非净利润：38,569,930.63元
• 经营活动现金流量净额：-401,529,667.84元
• 总资产：14,832,376,688.06元
• 流动负债：10,051,593,958.81元
• 短期借款：4,827,836,052.55元
• 货币资金：732,096,679.75元
• 销售费用：564,303,599.70元
• 研发费用：51,100,989.60元
• 非经常性损益：27,050,444.78元

结论与展望

公司2026年一季度业绩下滑明显，尤其扣非净利润同比腰斩，经营现金流持续大幅流出，短期负债压力显著增加，销售费用大幅上升而研发投入下降，主营业务盈利能力面临较大挑战。若未来政策环境及市场未出现积极变化，公司业绩仍存较大不确定性，投资者需密切关注公司流动性、偿债能力及主营业务回暖情况。

免责声明

本文仅为公开信息整理和分析，不构成任何投资建议。投资者据此操作，风险自担。

English Version

In-depth Analysis: Chongqing Taiji Industrial (Group) Co., Ltd. 2026 Q1 Results

Key Highlights and Issues Investors Must Note

• Revenue and Profits Fall, Core Profit Plummets:
• Revenue was RMB 2.528 billion, down 10.59% YoY.
• Net profit attributable to shareholders was RMB 65.62 million, down 11.97% YoY.
• Net profit excluding non-recurring items fell sharply to RMB 38.57 million, down 52.05% YoY.
• Operating Cash Flow Turns Deeply Negative:
• Net cash flow from operating activities was -RMB 401 million, compared to -RMB 165 million last year, showing a significant increase in cash outflows and indicating mounting operational funding pressure.
• Gross Margin Decline and Rising Expenses:
• Affected by centralized procurement and medical insurance policies, revenue from some anti-infection drugs declined, leading to lower gross profit.
• Sales expenses surged by 39.6% YoY to RMB 564 million, reflecting intensified marketing efforts.
• R&D expenses dropped 33.1% YoY to RMB 51.1 million, possibly indicating reduced investment in innovation.
• Heavy Reliance on Non-Recurring Gains:
• Non-recurring gains totaled RMB 27.05 million, mainly from government subsidies and gains from financial assets.
• Excluding these, core business profitability declines even more significantly.
• Balance Sheet Shifts:
• Total assets were RMB 14.83 billion, up 2.92% from the previous quarter.
• Current liabilities increased 3.55% to RMB 10.05 billion, with short-term borrowings at RMB 4.83 billion, indicating high short-term repayment pressure.
• Cash and equivalents fell sharply to RMB 732 million, down 33.5% QoQ.
• Shareholder Structure Stable:
• State-owned legal entities remain dominant, with Taiji Group Co. holding 27.89% (28.34 million shares pledged).
• No significant equity changes or large shareholder reductions observed.
• Declining Per Share Earnings and ROE:
• Basic EPS was RMB 0.12, down 7.69% YoY.
• Weighted average ROE was 1.86%, down 0.25 percentage points YoY.

Sensitive Issues for Investors

• Core business profitability has plummeted; unless policies or market environment improve soon, earnings pressure may persist.
• Sustained negative operating cash flow expansion raises liquidity risk concerns.
• Large short-term borrowings; monitor solvency and future refinancing capability.
• Sales expense surge and R&D cut may weaken long-term competitiveness.
• Growing reliance on non-recurring gains; core business sustainability is questionable.

Key Financial Data Summary

• Revenue: RMB 2,528,417,511.83
• Net profit attributable to shareholders: RMB 65,620,375.41
• Net profit excluding non-recurring items: RMB 38,569,930.63
• Net cash flow from operating activities: -RMB 401,529,667.84
• Total assets: RMB 14,832,376,688.06
• Current liabilities: RMB 10,051,593,958.81
• Short-term borrowings: RMB 4,827,836,052.55
• Cash and cash equivalents: RMB 732,096,679.75
• Sales expenses: RMB 564,303,599.70
• R&D expenses: RMB 51,100,989.60
• Non-recurring gains: RMB 27,050,444.78

Conclusion and Outlook

The company reported a significant decline in Q1 2026 results, with core profit halved and operating cash outflows worsening. Short-term debt pressure is rising, sales costs are up, and R&D spending is down, putting core business profitability under severe test. Unless favorable policy or market changes emerge, earnings uncertainty remains high. Investors should closely monitor liquidity, solvency, and a potential turnaround in core business.

Disclaimer

This article is based on public information and analysis, and does not constitute investment advice. Investors should make decisions at their own risk.

View 太极集团 Historical chart here